H.R. 2471: Right Drug Dose Now Act of 2025

This bill, known as the Right Drug Dose Now Act of 2025, aims to enhance the safety and effectiveness of medications through improved understanding and integration of pharmacogenomics—how genes affect a person's response to drugs. The bill includes several key components regarding the use of pharmacogenomic information in healthcare.

1. Updating the National Action Plan

The Secretary of Health and Human Services is tasked with:

• Submitting a report to Congress within 180 days of the bill's enactment concerning advancements in the National Action Plan for Adverse Drug Event Prevention.
• Convening a committee to update this plan, taking into account new scientific insights related to how drugs and genes interact, and assessing pharmacogenetic testing as a preventive tool for adverse drug events.

2. Education and Guidance for Healthcare Professionals

The bill mandates that the Secretary provides guidance to various healthcare providers, such as doctors, pharmacists, and genetic counselors. This guidance will cover:

• The effectiveness of pharmacogenomic testing in preventing adverse drug reactions.
• How to use alert systems regarding drug interactions related to genetic variations.
• Encouraging the integration of pharmacogenomic testing in patient care.
• The role of genetics specialists within the healthcare team.
• Incorporating pharmacogenomic considerations into medication management practices.
• Reporting pharmacogenomic information during adverse drug event reporting to federal regulators.

3. Improving Electronic Health Records (EHR)

The bill outlines actions to enhance EHR systems, including:

• Providing guidance for the inclusion of pharmacogenomic data in electronic prescribing systems.
• Establishing drug-gene interaction alert systems to aid healthcare providers in making informed decisions when prescribing medications.
• Encouraging the development of EHR systems that facilitate direct reporting of adverse drug events to the FDA.
• Updating the FDA Adverse Event Reporting System to capture drug-gene interactions.

4. Additional Studies and Recommendations

The bill requires the Comptroller General to conduct a study and issue recommendations on how the FDA can include updated drug-gene interaction information on drug labels. Furthermore, the Secretary must report on any additional necessary improvements to EHR systems to better support pharmacogenomics.

5. Reporting on Progress

Finally, the Secretary has specific timelines by which reports and improvements must be presented, ensuring timely updates and progress evaluations concerning the integration of pharmacogenomics in healthcare.

Relevant Companies

• ABT (Abbott Laboratories): Abbott specializes in lab testing and diagnostics, which could be significantly impacted by shifts towards integrated pharmacogenomic testing and reporting systems.
• ILMN (Illumina, Inc.): Illumina focuses on genetic analysis technologies, and would likely see direct impacts from increased demand for pharmacogenomics in clinical settings.
• TMO (Thermo Fisher Scientific Inc.): Thermo Fisher provides a range of healthcare products and services that might benefit from advancements in pharmacogenomic testing and health information integration.